Mesalazine as a new therapeutic option for chronic idiopathic urticaria

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of dermatological treatment (Print)

• Publication date

  2012-09-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/09546634.2011.565015PMID 21770811
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Martindale: The complete drug reference. 37th ed.

  2011cited by this paper
• Dermatology Life Quality Index

  2010cited by this paper
• Comprar Martindale the complete reference 36th Ed, 2 vols + CD-ROM | Sean Sweetman | 9780853698425 | Pharmaceutical Press

  2009cited by this paper
• Pathogenesis of chronic urticaria

  2009cited by this paper
• The spectrum of chronic urticaria.

  2009cited by this paper
• Chronic urticaria: diagnosis and management.

  2008cited by this paper
• Activated status of basophils in chronic urticaria leads to interleukin‐3 hyper‐responsiveness and enhancement of histamine release induced by anti‐IgE stimulus

  2008cited by this paper
• Update on chronic urticaria: focusing on mechanisms

  2008cited by this paper
• Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1.

  2008cited by this paper
• Therapeutic alternatives for chronic urticaria: an evidence-based review, Part 2.

  2008cited by this paper
• Is there a role for antileukotrienes in urticaria?

  2006cited by this paper
• Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine.

  2006cited by this paper
• EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria

  2006cited by this paper
• Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double‐blind, placebo‐controlled study

  2006cited by this paper
• EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria

  2006cited by this paper
• DLQI scores in vitiligo: reliability and validity of the Persian version

  2004cited by this paper
• Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.

  2004cited by this paper
• Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease

  2003cited by this paper
• Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin‐12 production and major histocompatibility complex II expression

  2001cited by this paper
• Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis

  2000cited by this paper
• The extent and nature of disability in different urticarial conditions

  1999influential reference
• The impact of chronic urticaria on the quality of life

  1997cited by this paper
• Mesalazine in treatment of psoriasis.

  1996cited by this paper
• Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema.

  1995cited by this paper
• 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells.

  1995cited by this paper
• Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use

  1994cited by this paper
• Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine.

  1993cited by this paper
• Mechanism of action of 5-arninosalicylic acid

  1992cited by this paper
• Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid

  1991cited by this paper

• Health-Related Quality of Life in Chronic Urticaria: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema

  2024cites this paper
• Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

  2024cites this paper
• Ultraperformance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics and Lipidomics Identify Biomarkers for Efficacy Evaluation of Mesalazine in a Dextran Sulfate Sodium-Induced Ulcerative Colitis Mouse Model.

  2020cites this paper
• Effects of Differential Food Patterns on the Pharmacokinetics of Enteric‐Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers

  2020cites this paper
• Treatment of Severely Recalcitrant Chronic Spontaneous Urticaria: A Discussion of Relevant Issues

  2015cites this paper
• Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first‐line treatments

  2015cites this paper
• Chapter-4 Determination of mesalamine assay by UPLC

  2014cites this paper